Affiliation:
1. the First Affiliated Hospital of Fujian Medical University
Abstract
Abstract
Purpose
Regulatory T cells (Tregs) have been highlighted as prognostic factors in isocitrate dehydrogenase (IDH)-wild-type (wt) glioblastoma (GBM). However, conventional detection of Tregs with immunohistochemistry is limited for practical application in clinical settings. The aim of this study was to construct a pathomics model to predict Treg infiltration in IDH-wt GBM and explore the related biological processes.
Methods
Using the Pyradiomics package, pathomics features were extracted from hematoxylin and eosin-stained biopsy images of patients from The Cancer Genome Atlas. The proportion of Tregs was confirmed in orthotopic glioblastoma mouse model via flow cytometry. The pathomics model was constructed using a gradient-boosting machine-learning approach, and the pathomics score (PS) was determined with the minimal redundancy-maximal relevance and relief algorithms. Cox proportional hazard regression analysis was employed to access the association between PS and overall survival (OS). Transcriptomic data were analyzed through GSEA set enrichment, differential gene expression, and correlation analyses.
Results
PS was positively correlated with high Treg expression. Patients with a high PS had significantly worse overall survival than did those with a low PS. A high PS independently served as a prognostic risk factor for patients with IDH-wt GBM. Gene set enrichment analysis revealed significant associations between PS and the Notch and IL-6/JAK/STAT3 signaling pathways. A high PS was also significantly correlated with elevated RAD50 expression.
Conclusion
The developed pathomics model based on machine-learning algorithms can offer an alternative non-invasive method to predict Treg infiltration and prognosis in patients with IDH-wt GBM, further suggesting potential targets for immunotherapy.
Publisher
Research Square Platform LLC
Reference78 articles.
1. Q.T. Ostrom, N. Patil, G. Cioffi, K. Waite, C. Kruchko, J.S. Barnholtz-Sloan, CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017. Neuro Oncol. 22, iv1-iv96 (2020)
2. European Organisation for, T. Treatment of Cancer Brain, G. Radiation Oncology, G. National Cancer Institute of Canada Clinical Trials, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial;Stupp R;Lancet Oncol.,2009
3. Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review;Fabian D;Cancers (Basel),2019
4. NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma;Tsien CI;J. Clin. Oncol.,2023
5. The biology and mathematical modelling of glioma invasion: a review;Alfonso JCL;J. R Soc. Interface,2017
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献